Teva Pharmaceuticals' Pay-for-Delay Drug Problem
Teva Pharmaceuticals' Pay-For-Delay Drug Problem
These “pay-for-delay” agreements— where a pharmaceutical company pays a generic producer to delay market entry of a lower-priced competing product—have been the focus of a high-profile battle between Federal Trade Commission and drug makers, …
Read more on Forbes
DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit …
CUPERTINO, Calif., May 7, 2014 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in …
Read more on PR Newswire (press release)
Related Drug Addiction Help Substance Abuse Information…